active ingredient: torasemide; 1 ampoule (4 ml) solution for injection contains torasemide sodium 21.262 mg (equivalent to 20 mg torasemide); excipients: sodium hydroxide, trometamol, polyethylene glycol 400, water for injection.
Treatment of effusions and edema due to congestive heart failure when there is a need for intravenous administration of drug (for example pulmonary edema due to congestive heart failure).
For patients with a significant decrease in renal function (creatinine clearance <20 mL / min and / or concentration of plasma creatinine> 6 mg / dl).
To preserve residual diuresis in severe renal failure and dialysis conditions in the presence of at least some of any residual diuresis (> 200 ml for 24 h), if any swelling, effusion, and / or increased blood pressure.
Dosage & Administration
Treatment should be started with a single dose of 2 ml – 10 mg per day of torasemide. If necessary, the dose may be increased to 4 ml – 20 mg / day. If the effect is insufficient, the dose can be increased to 8 ml – 40 mg / day, but for no more than 3 days.
Acute pulmonary edema: treatment should be started with the / in the introduction of a single dose of 4 ml – 20 mg of torasemide. Depending on the effect of the treatment dose can be repeatedly administered every 30 minutes, but not more than 20 ml – 100 mg per day of torasemide. P-P is administered in / in slowly.
Hypersensitivity to torasemide, sulfonylureas and other ingredients. Hypotension. Renal failure with anuria. Hepatic coma or precoma. Hypovolaemia. Hypokalemia Hyponatremia. Severe urinary disorders (eg due to prostatic hypertrophy). The period of lactation.
The drug Trifas 20 for infusions should not be administered at the normal or moderate renal insufficiency (creatinine clearance> 30 mL / min and / or the concentration of creatinine in the blood plasma of <3.5 mg / dL), due to the danger of excessive loss of water and electrolytes .